Italia markets open in 7 hours 12 minutes

OncoCyte Corporation (0KCC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,0193-0,1507 (-12,88%)
Alla chiusura: 05:05PM BST
Schermo intero
Chiusura precedente1,1700
Aperto1,0193
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,0193 - 1,0193
Intervallo di 52 settimane1,0193 - 1,0193
Volume100
Media VolumeN/D
Capitalizzazione92,816M
Beta (5 anni mensile)1,87
Rapporto PE (ttm)N/D
EPS (ttm)-0,7710
Prossima data utili08 ago 2022 - 12 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Oncocyte Reports First Quarter 2022 Financial Results

    IRVINE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the first quarter 2022, ended March 31, 2022. First Quarter and Recent Highlights: Reported total revenue of $1.4 million in the first quarter of 2022, compared with $1.1 million in the first quarter

  • GlobeNewswire

    Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test

    Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisionsIRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it has completed development of its proprietary TheraSure™ Transplant Monitoring test for liver

  • GlobeNewswire

    Oncocyte to Announce First Quarter 2022 Financial Results

    IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m